Apogee Therapeutics Reports Positive Phase 1b Asthma Results

Apogee Therapeutics ( (APGE) ) has provided an announcement.

On January 6, 2026, Apogee Therapeutics reported positive interim results from a Phase 1b trial of its anti-IL-13 antibody zumilokibart (APG777) in 19 adults with mild-to-moderate asthma and Type 2 inflammation, showing a favorable safety profile, robust and durable suppression of FeNO—a key biomarker linked to asthma exacerbations—through at least 16 weeks for all patients and up to 32 weeks in those with longer follow-up, along with encouraging trends in lung function and other Type 2 biomarkers. The company also highlighted cross-indication signals from its APEX Phase 2 atopic dermatitis program, laid out an aggressive 2026 clinical agenda including multiple Phase 2 data readouts, a planned Phase 3 start in atopic dermatitis by the second half of 2026, and an expanded head-to-head Phase 1b trial of its IL-13/OX40L combination APG279 versus Dupixent, positioning zumilokibart as a potential “pipeline-in-a-product” across dermatology and respiratory markets and reinforcing Apogee’s capacity—backed by long cash runway—to move toward a possible 2029 launch in atopic dermatitis and broader expansion in inflammatory and immunology diseases.

The most recent analyst rating on (APGE) stock is a Hold with a $81.00 price target. To see the full list of analyst forecasts on Apogee Therapeutics stock, see the APGE Stock Forecast page.

Spark’s Take on APGE Stock

According to Spark, TipRanks’ AI Analyst, APGE is a Neutral.

The score is anchored by a strong balance sheet and favorable technical trend, boosted by positive clinical updates and strengthened funding runway. Offsetting these positives are the pre-revenue profile, sharply widening losses, and substantial ongoing cash burn, which elevate execution and future funding risk.

To see Spark’s full report on APGE stock, click here.

More about Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotechnology company developing optimized, novel biologic antibodies for large inflammatory and immunology markets, with a focus on atopic dermatitis, asthma, eosinophilic esophagitis, COPD and other Type 2 inflammatory indications, and is currently advancing its lead anti-IL-13 asset zumilokibart (APG777) alongside combination programs such as APG279. As of September 30, 2025, the Nasdaq-listed company reported a strong cash position of $913 million, providing runway into the second half of 2028 to support late-stage trials and a potential commercial launch in atopic dermatitis.

Average Trading Volume: 906,342

Technical Sentiment Signal: Buy

Current Market Cap: $5.3B

See more data about APGE stock on TipRanks’ Stock Analysis page.